AlphAIAlphAI — Financial news for AI agents
Stock TitanMAR 272 min read$CTMX

Vanguard (CTMX) reports 0 shares; disaggregation after internal realignment

The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of CytomX Therapeutics Inc (CTMX) common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries began reporting beneficial ownership separately, as permitted by SEC Release No. 34-39538. The filing indicates no voting or dispositive power over CTMX shares for The Vanguard Group itself.

Original reporting
Stock Titan
Published Mar 27, 2026, 6:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 27, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CTMX
Neutral
high confidence
Mentioned
$CTMX
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$CTMXNeutralLow
01

Why it matters

This administrative update indicates no active trading or ownership change, suggesting limited market impact.

02

Market read

The news has limited relevance to market dynamics, primarily affecting Vanguard's reporting structure rather than trading activity.

03

What to watch

The change is purely administrative, stemming from internal realignment, and does not reflect a market-driven decision or change in CTMX's fundamentals.

Timing: low

Background

Vanguard filed an amended Schedule 13G/A, reporting zero shares and beneficial ownership of CTMX as of March 13, 2026, due to internal realignment.

Company-level read

Ticker impact

$CTMXNeutralHigh confidence
Context

The news pertains to Vanguard's internal realignment affecting its ownership reporting of CytomX Therapeutics Inc (CTMX).

Expected impact

Minimal to no immediate impact on CTMX stock price.

Evidence & confidence

The filing reflects internal reporting adjustments rather than market-driven ownership changes, suggesting limited direct trading impact.

Market effects

Sector

Limited sector impact; the change is specific to Vanguard's reporting structure.

Regional

Minimal regional effects, as the news pertains to a U.S.-based SEC filing.

Global

Negligible; primarily a regulatory reporting update without market-wide implications.

Counterpoint

What could challenge this read

Some traders might interpret the zero ownership report as a sign of Vanguard reducing exposure, potentially signaling a lack of confidence or strategic shift.

Key entities

  • Institutional Investor
    Vanguard Group

    A major investment management company.

  • Biotech Company
    CytomX Therapeutics Inc

    A biopharmaceutical company focused on innovative cancer therapies.

Read at source← All news

Related articles

AUG 27
$CTMXMedAI 8/10

CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

CytomX Therapeutics (CTMX) announced FDA Fast Track Designation for Varseta-M, a treatment for relapsed/refractory metastatic colorectal cancer. The designation follows encouraging Phase 1 data. A potential monotherapy registrational study is planned for initiation in 1H 2027, according to the company.

finanznachrichten.de2 min
AUG 6
$CTMXMed

CytomX Therapeutics, Inc. (CTMX): Results of Operations and Financial Condition

CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation

SEC EDGAR 8-K7 min
SEP 15
$LMTMedAI 9/10

LMT Looks 6.0% Undervalued on GF Value™ with Strong Dividend App

Lockheed Martin (LMT) secured a $1.21B U.S. Army contract, boosting its defense sector standing. The company offers a 2.62% dividend yield, a 50% payout ratio, and 5.4% 3-year dividend growth. Its GF Value™ suggests a 6.0% undervaluation, with a GF Score™ of 80/100. Insider activity shows net selling, while institutional confidence remains strong.

gurufocus.com2 min